Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Cash & Equivalents (2023 - 2025)

Historic Cash & Equivalents for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $301.6 million.

  • Zenas BioPharma's Cash & Equivalents fell 1623.11% to $301.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $301.6 million, marking a year-over-year decrease of 1623.11%. This contributed to the annual value of $319.7 million for FY2024, which is 46236.17% up from last year.
  • Zenas BioPharma's Cash & Equivalents amounted to $301.6 million in Q3 2025, which was down 1623.11% from $274.9 million recorded in Q2 2025.
  • Over the past 5 years, Zenas BioPharma's Cash & Equivalents peaked at $360.0 million during Q3 2024, and registered a low of $37.2 million during Q1 2024.
  • In the last 3 years, Zenas BioPharma's Cash & Equivalents had a median value of $274.9 million in 2025 and averaged $213.4 million.
  • Over the last 5 years, Zenas BioPharma's Cash & Equivalents had its largest YoY gain of 74566.94% in 2025, and its largest YoY loss of 1623.11% in 2025.
  • Over the past 3 years, Zenas BioPharma's Cash & Equivalents (Quarter) stood at $56.9 million in 2023, then skyrocketed by 462.36% to $319.7 million in 2024, then dropped by 5.67% to $301.6 million in 2025.
  • Its Cash & Equivalents was $301.6 million in Q3 2025, compared to $274.9 million in Q2 2025 and $314.2 million in Q1 2025.